 |
|
|
| |
Course of Cirrhosis Regression: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment
|
| |
| |
AASLD: The Liver Meeting 2019, November 8-12, 2019, Boston, MA
Reported by Jules Levin
Ira Jacobson,1 Andrew J. Muir,2 Eric J. Lawitz,3 Edward Gane,4 Brian Conway,5 Peter J. Ruane,6 Ziad Younes,7 Frances Chen,8 Marianne Camargo,8 Anand P. Chokkalingam,8 C. Stephen Djedjos,8 Anuj Gaggar,8 Robert P. Myers,8 Barbara Leggett,9 Jose Luis Calleja,10 Kosh Agarwal,11 K. Rajender Reddy,12 Alessandra Mangia13
1NYU Langone Health, New York, NY; 2Duke University, Durham, NC; 3Texas Liver Institute, UT Health San Antonio, TX; 4New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 5Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; 6Ruane Medical & Liver Health Institute, Los Angeles, CA; 7GastroOne, Germantown, TN; 8Gilead Sciences, Inc., Foster City, CA; 9The University of Queensland Faculty of Medicine, Herston, Australia; 10Hospital Universitario Puerta de Hierro Majadahonda, Spain; 11King's College Hospital, London, UK; 12University of Pennsylvania, Philadelphia; 13Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
References: 1. Bruno S, et al. Hepatology 2007;45:579-87; 2. van der Meer AJ, et al. JAMA 2012;308:2584-93; 3. Veldt BJ, et al. Ann Intern Med 2007;147:677-84; 4. Pann JJ, et al. Hepatol Commun 2018;2:1320-30; 5. Poynard T, et al. Hepatology 2000;32:1131-7.
|
| |
|
|
|
|
|
